Most Read Articles
Audrey Abella, 16 Oct 2019
The PD-1* inhibitor nivolumab showed significant survival benefit and a favourable safety profile than taxane chemotherapy in patients with unresectable advanced or recurrent oesophageal squamous cell carcinoma (OSCC) refractory or intolerant to previous fluoropyrimidine- and platinum-based chemotherapy, according to the findings of ATTRACTION-3** presented at ESMO 2019.
03 Oct 2019
Early enteral nutrition (EEN) speeds up the recovery of gastrointestinal function after laparoscopic common bile duct exploration (LCBDE), according to a study. However, EEN also increases complications such as diarrhoea and abdominal distension.
01 Sep 2019
A third of Clostridium difficile infection (CDI) patients with cirrhosis have been readmitted in a span of 30 days primarily due to recurrent CDI, a recent study has found. In addition, there is a high rate of mortality linked to CDI in patients with cirrhosis, in which a poor prognosis is predicted by decompensation and 30-day readmission.
26 Sep 2019
Use of proton pump inhibitors contributes to increased risk of cholangitis, a large cohort study suggests.

Probiotic supplements may promote weight loss in obese children

Pearl Toh
23 Sep 2019

Probiotic supplements, in addition to diet and exercise, may help obese children lose weight along with improvement in metabolic health compared with those undergoing lifestyle modification alone, according to a pilot study presented at the 58th Annual European Society for Paediatric Endocrinology (ESPE) Meeting held in Vienna, Austria.

“Childhood obesity is a growing problem that needs early intervention to prevent long-term health problems; microbiome-based treatments could be a new and more effective strategy for tackling this serious epidemic,” said Professor Chen Rui-Min from Fuzhou Children's Hospital of Fujian in Fuzhou, China.

In the double-blind trial, 54 obese children aged 6–14 years were randomized to receive probiotic supplement (n=30, mean age 9.88 years, mean BMI 25.73) or placebo control (n=24, mean age 9.60 years, mean BMI 25.35) for 12 weeks, in addition to an exercise regime and reduced calorie diet. Probiotic supplements were in capsule form containing Lactobacillus bulgaricus, Bifidobacterium longum, and Streptococcus thermophilus. [ESPE 2019, abstract P1-191]

After 12 weeks, children in the probiotic group had significantly greater weight loss compared with the control group. The addition of probiotics improved BMI to a greater extent vs the control intervention (p<0.05).

In addition, improvement in metabolic measures, as indicated by insulin, triglyceride, fasting blood glucose, and homeostasis model assessment of insulin resistance (HOMA-IR) were significantly greater in the probiotic group than the control group (p<0.05 for all).

Significant reductions were also seen in inflammatory markers such as interleukin-6, tumour necrosis factor α, and lipopolysaccharide binding protein in the probiotic group vs the control group (p<0.05 for all).

“Our findings suggest that probiotic supplementation may help with weight loss and improve metabolic health in obese children, and that this may be an effective strategy for the prevention and treatment of obesity in the future,” said Chen.

The improvement in metabolic health indicates that probiotic supplements may also help reduce the risk of metabolic conditions, such as heart disease and type 2 diabetes, in obese children, suggests Chen, although more studies are needed to verify this.   

“More work is needed to confirm these findings — our number of participants was small and limited to the Fuijan area. Other studies have also reported no benefits from probiotic treatment in obese children but these were much shorter in duration. So, further investigation is needed before any medical recommendations can be made,” said Chen.

To further understand the association between gut bacteria and obesity, as well as the role of probiotics in altering the gut microbiome and their effects on metabolic health, Chen and colleagues are currently planning larger trials to investigate these.

 

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 16 Oct 2019
The PD-1* inhibitor nivolumab showed significant survival benefit and a favourable safety profile than taxane chemotherapy in patients with unresectable advanced or recurrent oesophageal squamous cell carcinoma (OSCC) refractory or intolerant to previous fluoropyrimidine- and platinum-based chemotherapy, according to the findings of ATTRACTION-3** presented at ESMO 2019.
03 Oct 2019
Early enteral nutrition (EEN) speeds up the recovery of gastrointestinal function after laparoscopic common bile duct exploration (LCBDE), according to a study. However, EEN also increases complications such as diarrhoea and abdominal distension.
01 Sep 2019
A third of Clostridium difficile infection (CDI) patients with cirrhosis have been readmitted in a span of 30 days primarily due to recurrent CDI, a recent study has found. In addition, there is a high rate of mortality linked to CDI in patients with cirrhosis, in which a poor prognosis is predicted by decompensation and 30-day readmission.
26 Sep 2019
Use of proton pump inhibitors contributes to increased risk of cholangitis, a large cohort study suggests.